Gapping down
In reaction to earnings/guidance:
- GBX -5.1%, SGH -3.3%, MSM -0.6%
M&A news:
- HSIC -1.1% (acquires majority ownership position in Prism Medical Products)
Other news:
- IMRA -24.1% (reported results from its Phase 2a clinical trial of IMR-687 in adult patients with sickle cell disease)
- TMDI -17.6% (announces "bought deal" offering at $1.55 per unit)
- CLSD -10% (prices 4,209,050 shares of common stock at $2.851/share)
- OCN -8.5% (comments on conclusion of mediation with the Consumer Financial Protection Bureau; "settlement discussions with the CFPB did not resolve this matter")
- NEO -6% (stock offering and convertible notes offering)
- ARE -4.2% (prices offering of 6 mln shares of common stock at $164.00 per share)
- NGM -3% (prices offering of 4,629,630 shares of its common stock at $27.00 per share)
- NKTR -1.5% (Chief Medical Officer to step down)
- PLAN -1.5% (names Bill Schuh as Chief Revenue Officer)
- QQQ -1.4% (in-line with Nasdaq futures in pre-mkt)
- PZZA -1.3% (Starboard elected to again exercise the Continuation Option under the Governance Agreement thereby continuing the Standstill Period)
Analyst comments:
- MYOV -3.2% (downgraded to Neutral from Buy at Goldman)
- BYND -2.6% (downgraded to Neutral from Overweight at Piper Sandler)
- FOUR -2.3% (downgraded to Underperform from Neutral at BofA Securities)
- CURI -2% (downgraded to Neutral from Buy at B. Riley Securities)
- KDP -1.8% (downgraded to In-line from Outperform at Evercore ISI)
- PCG -1.3% (downgraded to Underweight from Equal Weight at Wells Fargo)
- PEP -1.2% (downgraded to In-line from Outperform at Evercore ISI)
- ORA -1.1% (downgraded to Neutral from Overweight at JP Morgan)
- RRC -1.1% (downgraded to Neutral from Buy at BofA Securities)
- FE -1% (downgraded to Underweight from Equal Weight at Wells Fargo)
- BAX -0.9% (downgraded to Neutral from Buy at UBS)